Miist Therapeutics, a physics-based developer of inhaled medicines, announced $7M in seed funding from investors including Refactor Capital, 1517 Fund, Freeflow Ventures, Entrepreneur First, and California Innovation Fund, among others.
Miist has clinically validated its approach and is currently advancing two assets: MST-01 for the treatment of smoking addiction and MST-02 for the treatment of migraine. Phase 1 results for MST-01 demonstrate the speed of Miist’s therapies, with patients achieving 92% symptom relief in only 2 minutes post-dosing.
“So many therapeutic areas today are dominated by oral treatments that work far slower than patients want. A great example is migraine: when someone is suffering from debilitating migraine symptoms, they don’t want to wait an hour for their pill to kick in. Their #1 priority is getting fast relief and that’s what we’re uniquely positioned to deliver,” said Miist Therapeutics’ CEO and co-founder, Dalton Signor.
With this funding, the company is now positioned to accelerate its assets one step closer to the nearly 100 million patients who need them globally.
Miist Therapeutics applies a physics-based approach to develop inhaled therapies that are faster acting and more effective than today’s standard of care. The company’s core technology is an inhaler that uses ultrasonic vibration to generate and deliver 2-micron aqueous drug particles to the peripheral lung, where they are instantly absorbed into the bloodstream. Using this novel approach, Miist is developing new inhaled therapies that will deliver instant relief for some of our most common and debilitating conditions.